Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the sale, the insider owned 32,718 shares in the company, valued at $3,659,181.12. This trade represents a 17.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.28, for a total value of $550,568.16.
Oruka Therapeutics Trading Up 1.5%
Shares of NASDAQ ORKA opened at $112.66 on Tuesday. The company has a market cap of $7.46 billion, a PE ratio of -55.50 and a beta of -0.34. The company has a 50-day moving average of $88.49 and a two-hundred day moving average of $63.36. Oruka Therapeutics, Inc. has a 1-year low of $14.08 and a 1-year high of $113.04.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.
Institutional Trading of Oruka Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC bought a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $713,775,000. Artia Global Partners LP acquired a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $3,179,000. Bank of America Corp DE bought a new stake in shares of Oruka Therapeutics during the second quarter worth $33,578,000. Freestone Grove Partners LP bought a new stake in shares of Oruka Therapeutics during the second quarter worth $2,134,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Oruka Therapeutics during the second quarter worth $130,968,000. Institutional investors and hedge funds own 56.44% of the company's stock.
Analyst Ratings Changes
ORKA has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. BTIG Research reaffirmed a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. UBS Group lifted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Finally, Piper Sandler reiterated an "overweight" rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $134.30.
Read Our Latest Stock Analysis on Oruka Therapeutics
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
